Celecoxib in breast cancer prevention and therapy

Abstract

Jieqing Li,1,2 Qiongyu Hao,2 Wei Cao,2,3 Jaydutt V Vadgama,2,4,* Yong Wu2,4,* 1Department of Breast Surgery, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, China; 2Division of Cancer Research and Training, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles,CA, USA; 3Department of Nuclear Medicine, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 4David Geffen UCLA School of Medicine and UCLA Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA *These authors contributed equally to this work Abstract: Breast cancer has a high incidence worldwide. The results of substantial studis reveal that inflammation plays an important role in the initiation, development, and aggressiveness of many malignancies. The use of celecoxib, a novel NSAID, is repetitively associated with the reduced risk of the occurrence and progression of a number of types of cancer, particularly breast cancer. This observation is also substantiated by various meta-analyses. Clinical trials have been implemented on integration treatment of celecoxib and shown encouraging results. Celecoxib could be treated as a potential candidate for antitumor agent. There are, nonetheless, some unaddressed questions concerning the precise mechanism underlying the anticancer effect of celecoxib as well as its activity against different types of cancer. In this review, we discuss different mechanisms of anticancer effect of celecoxib as well as preclinical/clinical results signifying this beneficial effect. Keywords: celecoxib, breast cancer, COX-2, inflammation

Keywords

• Celecoxib
• breast cancer
• COX-2
• inflammation